Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ORGANIZATION
ORGANIZATION
- Impact of Off-Year Drug Re-Pricing Should Be Limited: FPMAJ
June 12, 2020
- Eisai’s Akana Elected as New Chair of FPMAJ’s Drug Pricing Committee
June 12, 2020
- New Special Rule for “Indication Change” Re-Pricing Significantly Lacks Predictability: FPMAJ
June 12, 2020
- 3 Healthcare Organizations Prod Govt to Forgo FY2020 Drug Price Survey
June 11, 2020
- Postpone Off-Year Drug Re-Pricing Until 2023 or Beyond: JPMA
June 11, 2020
- Daiichi Sankyo CEO Manabe Set to Gain Lobbying Experience as FPMAJ Vice Chair, Chairman Seat Eyed for 2021
June 10, 2020
- Japan Pharma Trade Group Nudges Govt to Postpone Off-Year Re-Pricing
June 8, 2020
- Patient Advocacy Group Urges MLHW to Increase Funding for Pancreatic Cancer Research
June 8, 2020
- API/Intermediate Imports from India Still Stalled, Traders’ Group Calls for Govt Schemes
June 4, 2020
- JGA Chief Sawai to Stay in His Post, Deputy Chief Tamura Stepping Down
June 4, 2020
- JPMA Reprimands Torii, Nippon Chemiphar over Price-Fixing
May 29, 2020
- JPMA to Compile Proposal for Measures against Infectious Diseases: Chief
May 29, 2020
- JPWA Resolution Urges Govt to Revisit Off-Year Drug Re-Pricing
May 29, 2020
- Generic/Biosimilar Society Calls on MHLW to Ensure Stable API Supply
May 26, 2020
- Japan Pharmacist Group Renews Opposition to Off-Year Re-Pricing in FY2021
May 22, 2020
- Pneumococcal Vaccination Rate in Children Falls Sharply amid COVID-19 Pandemic: Survey
May 21, 2020
- JCHO Hospitals to Switch from Joint to Separate Bidding for Drug Purchases after Bid-Rigging Scandal
May 21, 2020
- Don’t Give Hasty COVID-19 Nod for Existing Drugs, Follow Int’l Rules for Avigan Approval: JMA
May 21, 2020
- Hodanren Criticizes Zolgensma’s High NHI Price as “Result of a Money Game”
May 18, 2020
- FPMAJ to Continue COVID-19 Impact Survey on Drug Supplies
May 18, 2020
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…